Literature DB >> 19261776

Rapid mycobacterial liquid culture-screening method for Mycobacterium avium complex based on secreted antigen-capture enzyme-linked immunosorbent assay.

Sung Jae Shin1, Kelly Anklam, Elizabeth J B Manning, Michael T Collins.   

Abstract

Sensors in automated liquid culture systems for mycobacteria, such as MGIT, BacT/Alert 3D, and Trek ESP II, flag growth of any type of bacteria; a positive signal does not mean that the target mycobacteria are present. All signal-positive cultures thus require additional and often laborious testing. An immunoassay was developed to screen liquid mycobacterial cultures for evidence of Mycobacterium avium complex (MAC). The method, called the MAC-enzyme-linked immunosorbent assay (ELISA), relies on detection of MAC-specific secreted antigens in liquid culture. Secreted MAC antigens were captured by the MAC-ELISA with polyclonal anti- Mycobacterium avium subsp. paratuberculosis chicken immunoglobulin Y (IgY), detected using rabbit anti-MAC IgG, and then revealed using horseradish peroxidase-conjugated goat anti-rabbit IgG. When the MAC-ELISA was evaluated using pure cultures of known mycobacterial (n = 75) and nonmycobacterial (n = 17) organisms, no false-positive or false-negative MAC-ELISA results were found. By receiver operator characteristic (ROC) analysis of 1,275 previously identified clinical isolates, at the assay optimal cutoff the diagnostic sensitivity and specificity of the MAC-ELISA were 92.6% (95% confidence interval [95% CI], 90.3 to 94.5) and 99.9% (95% CI, 99.2 to 100), respectively, with an area under the ROC curve of 0.992. Prospective evaluation of the MAC-ELISA with an additional 652 clinical samples inoculated into MGIT ParaTB medium and signaling positive per the manufacturer's instructions found that the MAC-ELISA was effective in determining those cultures that actually contained MAC species and warranting the resources required to identify the organism by PCR. Of these 652 MGIT-positive cultures, the MAC-ELISA correctly identified 96.8% (of 219 MAC-ELISA-positive cultures) as truly containing MAC mycobacteria, based on PCR or high-performance liquid chromatography (HPLC) as reference tests. Only 6 of 433 MGIT signal-positive cultures (1.4%) were MAC-ELISA false negative, and only 7 of 219 MGIT signal-negative cultures (3.2%) were false positive. The MAC-ELISA is a low-cost, rapid, sensitive, and specific test for MAC in liquid cultures. It could be used in conjunction with or independent of automated culture reading instrumentation. For maximal accuracy and subspecies-specific identification, use of a confirmatory multiplex MAC PCR is recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261776      PMCID: PMC2681583          DOI: 10.1128/CVI.00461-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  37 in total

Review 1.  Epidemiology of selected mycobacteria that infect humans and other animals.

Authors:  D A Ashford; E Whitney; P Raghunathan; O Cosivi
Journal:  Rev Sci Tech       Date:  2001-04       Impact factor: 1.181

2.  Comparative evaluation of four decontamination protocols for the isolation of Mycobacterium avium subsp. paratuberculosis from milk.

Authors:  L Dundee; I R Grant; H J Ball; M T Rowe
Journal:  Lett Appl Microbiol       Date:  2001-09       Impact factor: 2.858

3.  Relationship between IS901 in the Mycobacterium avium complex strains isolated from birds, animals, humans, and the environment and virulence for poultry.

Authors:  I Pavlik; P Svastova; J Bartl; L Dvorska; I Rychlik
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 4.  Mycobacterium avium subsp. paratuberculosis in Veterinary Medicine.

Authors:  N B Harris; R G Barletta
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

5.  Application of the C(18)-carboxypropylbetaine specimen processing method to recovery of Mycobacterium avium subsp. paratuberculosis from ruminant tissue specimens.

Authors:  Charles G Thornton; Kerry M MacLellan; Judith R Stabel; Christine Carothers; Robert H Whitlock; Selvin Passen
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

6.  Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000.

Authors:  C R Horsburgh; J Gettings; L N Alexander; J L Lennox
Journal:  Clin Infect Dis       Date:  2001-10-24       Impact factor: 9.079

7.  Evaluation of BacT/Alert 3D liquid culture system for recovery of mycobacteria from clinical specimens using sodium dodecyl (lauryl) sulfate-NaOH decontamination.

Authors:  A Carricajo; N Fonsale; A C Vautrin; G Aubert
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 8.  Mycobacterium avium subsp. paratuberculosis: pathogen, pathogenesis and diagnosis.

Authors:  E J Manning; M T Collins
Journal:  Rev Sci Tech       Date:  2001-04       Impact factor: 1.181

9.  Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and 'M. avium subsp. hominissuis' for the human/porcine type of M. avium.

Authors:  Wouter Mijs; Petra de Haas; Rudi Rossau; Tridia Van der Laan; Leen Rigouts; Françoise Portaels; Dick van Soolingen
Journal:  Int J Syst Evol Microbiol       Date:  2002-09       Impact factor: 2.747

10.  Virulence of Mycobacterium avium complex strains isolated from immunocompetent patients.

Authors:  Yoshitaka Tateishi; Yukio Hirayama; Yuriko Ozeki; Yukiko Nishiuchi; Mamiko Yoshimura; Jing Kang; Atsushi Shibata; Kazuto Hirata; Seigo Kitada; Ryoji Maekura; Hisashi Ogura; Kazuo Kobayashi; Sohkichi Matsumoto
Journal:  Microb Pathog       Date:  2008-11-01       Impact factor: 3.738

View more
  1 in total

1.  Development and validation of a liquid medium (M7H9C) for routine culture of Mycobacterium avium subsp. paratuberculosis to replace modified Bactec 12B medium.

Authors:  Richard J Whittington; Ann-Michele Whittington; Anna Waldron; Douglas J Begg; Kumi de Silva; Auriol C Purdie; Karren M Plain
Journal:  J Clin Microbiol       Date:  2013-09-18       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.